Company (location) |
Company (location) |
Value (M) |
Type/product area |
Terms/details |
Date |
NOVEMBER | |||||
Athera Biotechnologies AB (Stockholm) |
Boehringer Ingelheim GmbH (Ingelheim, Germany) |
ND |
Boehringer opted not to exercise its option to license Athera's cardiovascular antibody due to a shift in its strategy |
Athera said its ongoing clinical development program of the fully human antibody PC-MAb, now in phase I testing, is not affected by the termination of the agreement |
11/13/14 |
Inovio Pharmaceuticals Inc. (Plymouth Meeting, Pa.) |
Roche AG (Basel, Switzerland) |
ND |
Terminated collaboration, option and license agreement to co-develop INO-5150, its DNA immunotherapy targeting prostate cancer, as well as a research collaboration in prostate cancer, signed in 2013 |
All of Roche's rights to INO-5150, including the right to license the product to other parties, will be returned; Inovio said it plans to independently advance INO-5150 into a phase I trial in the first half of 2015; Inovio and Roche will continue to collaborate and co-develop DNA immunotherapy INO-1800 against hepatitis B virus under an existing license agreement |
11/18/14 |
Intra-Cellular Therapies Inc. (New York) |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) |
$750 |
Mutually terminated a license agreement covering Intra-Cellular Therapies' compound ITI-214 and related phosphodiesterase type 1 inhibitors |
Takeda returned full rights for the compounds to Intra-Cellular, which said it plans to continue the clinical development of PDE1 inhibitors for the treatment of central nervous system, cardiovascular and other disorders; the agreement, originally struck in February 2011, had held the potential for more than $750M in rewards for Intra-Cellular |
11/4/14 |
DECEMBER | |||||
Amag Pharmaceuticals Inc. (Waltham, Mass.) |
Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) |
ND |
Agreement to mutually terminate their March 2010 license, development and commercialization agreement that granted Takeda exclusive rights to market ferumoxytol in Canada, the EU and Switzerland, as well as certain other territories |
Amag now regains all worldwide development and commercialization rights for Feraheme/Rienso and receives an undisclosed payment in connection with the termination, and Takeda also will provide certain transition services for up to 180 days after the marketing authorization transfer in each territory |
12/30/14 |
Array Biopharma Inc. (Boulder, Colo.) |
Novartis AG (Basel, Switzerland) |
$85 |
Array regained rights to phase III MEK inhibitor, binimetinib, for melanoma |
Array gained $85M from Novartis as part of the termination of the 2010 deal, and agreed to manufacture clinical and commercial supply for 30 months; the decision was made based on Glaxosmithkline plc delivering the already-approved MEK inhibitor Mekinist to Novartis through an asset-swap deal |
12/5/14 |
Dynavax Technologies Corp. (Berkeley, Calif.) |
Glaxosmithkline plc (London) |
$810 |
Dynavax regained full rights to DV1179 following expiration of a potential $810M research and development collaboration and license agreement executed in 2008 |
Dynavax now holds global rights to continue the development of DV1179 and other TLR 7/9 inhibitors for all indications |
12/2/14 |
Galapagos NV (Mechelen, Belgium) |
Janssen Pharmaceutica NV (unit of Johnson & Johnson; New Brunswick, N.J.) |
ND |
Janssen is returning full rights to its entire GPR84 program, including the inhibitor GLPG1205 and its backup compound GLPG2196 |
Galapagos said last year that '1205 showed good safety, target engagement and favorable drug-like properties in phase I studies in healthy volunteers |
12/17/14 |
Oncogenex Pharmaceuticals Inc. (Bothell, Wash.) |
Teva Pharmaceutical Industries Ltd. (Jerusalem) |
$27 |
Agreement to terminate a 2009 collaboration for custirsen, a phase III product to treat prostate and lung cancers |
Following termination, Oncogenex will receive $27M and will take over all custirsen-related expenses, including those related to the Enxpirit trial; custirsen failed in a pivotal trial against prostate cancer in April 2014 |
12/31/14 |
Pozen Inc. (Chapel Hill, N.C.) |
Sanofi US (unit of Sanofi SA; Paris) |
ND |
Sanofi returned all rights to the gastrointestinal-friendly aspirin candidates PA8140 and PA32540 |
The termination follows an FDA complete response letter that raised third-party manufacturing issues in April |
12/2/14 |
Vanda Pharmaceuticals Inc. (Washington) |
Novartis AG (Basel, Switzerland) |
ND |
Terminated deal for schizophrenia drug Fanapt |
Vanda regained U.S. and Canadian rights from Novartis |
12/24/14 |
Vernalis plc (Winnersh, UK) |
Novartis AG (Basel, Switzerland) |
ND |
Terminated development agreement for AUY922, an intravenous Hsp90 inhibitor for solid cancer tumors |
Rights from the program will now revert to Vernalis; the drug was out-licensed to Novartis in 2004 and since then Vernalis has made no further investment |
12/22/14 |
JANUARY | |||||
Debiopharm Group (Lausanne, Switzerland) |
Novartis AG (Basel, Switzerland) |
ND |
Debiopharm re-acquired full rights to Alisporivir (DEB025) from Novartis |
The product currently is completing two phase II studies of interferon-free treatment in hepatitis C virus; the terminated deal was a strategic decision for Novartis; Biorestorative and Novartis entered the collaboration in January 2010 |
1/13/15 |
Symphogen A/S (Copenhagen) |
Merck KGaA (Darmstadt, Germany) |
$631.6 |
Agreement in which Merck is giving back rights to Sym004 as it reprioritizes its pipeline |
The parties entered the potential $631.6M deal in September 2012 |
1/30/15 |
|
Notes The date indicated refers to the BioWorld Today issue in which the news item can be found. | |||||
